Home Care Ontario is calling on the province to embrace home care as the solution to hallway medicine. That's good news for ...

CHMP opinion now expected in 1Q 2025No Major Objections outstanding; continue to expect Germany launch in 2Q 2025PITTSBURGH, Dec. 09, 2024 ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

Vlahovic highlighted several options that can help improve the appearance of dystrophic nails as they recover or grow back: In Vlahovic's experience, KeryFlex and NECPro last 6-8 weeks.

Krystal Biotech ( (KRYS) ) just unveiled an announcement.

The firm is on track to launch the gene therapy for dystrophic epidermolysis bullosa, called Vyjuvek in the US, in Germany in Q2 2025.

Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and ...

Although many equity markets slipped in January, they recovered over the next two months for a strong first quarter of 2024.

Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further ...

Ironwood Pharmaceuticals Inc. Cl A-2.62% $536.1M ...

BioMarin Pharmaceutical Inc. announced a €60 million investment in the expansion of its state-of-the-art facility in ...

After hours: December 10 at 6:50:11 PM EST Loading Chart for QNRX ...